CoChat
Sign Up
Cited by 538HIV Research and TreatmentHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

Open access
Corey, Lawrence, Gilbert, Peter B., Juraska, Michal, Montefiori, David C., Morris, Lynn, Karuna, Shelly T., Edupuganti, Srilatha, Mgodi, Nyaradzo M., deCamp, Allan C., Rudnicki, Erika, Huang, Yunda, Gonzales, Pedro, Cabello, Robinson, Orrell, Catherine, Lama, Javier R., Laher, Fatima, Lazarus, Erica M., Sanchez, Jorge, Frank, Ian, Hinojosa, Juan, Sobieszczyk, Magdalena E., Marshall, Kyle E., Mukwekwerere, Pamela G., Makhema, Joseph, Baden, Lindsey R., Mullins, James I., Williamson, Carolyn, Hural, John, McElrath, M. Juliana, Bentley, Carter, Takuva, Simbarashe, Gomez Lorenzo, Margarita M., Burns, David N., Espy, Nicole, Randhawa, April K., Kochar, Nidhi, Piwowar-Manning, Estelle, Donnell, Deborah J., Sista, Nirupama, Andrew, Philip, Kublin, James G., Gray, Glenda, Ledgerwood, Julie E., Mascola, John R., Cohen, Myron S.·2021·New England Journal of Medicine
DOI 10.1056/nejmoa2031738PMC PMC8189692
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUNDWhether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODSWe enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial.Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total.HIV-1 testing was performed every 4 weeks.The VRC01 80% inhibitory concentration (IC 80 ) of acquired isolates was measured with the TZM-bl assay. RESULTSAdverse events were similar in number and severity among the treatment groups within each trial.Among the 2699 participants in HVTN 704/HPTN 085, HIV-1 infection occurred in 32 in the low-dose group, 28 in the high-dose group, and 38 in the placebo group.Among the 1924 participants in HVTN 703/HPTN 081, infection occurred in 28 in the low-dose group, 19 in the high-dose group, and 29 in the placebo group.The incidence of HIV-1 infection per 100 person-years in HVTN 704/ HPTN 085 was 2.35 in the pooled VRC01 groups and 2.98 in the placebo group (estimated prevention efficacy, 26.6%; 95% confidence interval [CI], -11.7 to 51.8; P = 0.15), and the incidence per 100 person-years in HVTN 703/HPTN 081 was 2.49 in the pooled VRC01 groups and 3.10 in the placebo group (estimated prevention efficacy, 8.8%; 95% CI, -45.1 to 42.6; P = 0.70).In prespecified analyses pooling data across the trials, the incidence of infection with VRC01-sensitive isolates (IC 80 <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9).The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONSVRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective.(Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials .govnumbers, NCT02716675 and NCT02568215.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2031738

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 2

  1. 10.1128/JVI.00991-17 · DOI
  2. Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS. Clinical trials of broadly neutralizing monoclonal antibodies for HIV prevention: a review. J Infect Dis 2020 June 30 (Epub ahead of print).32604408

Cited by

Sorted by citations

Items 101–200 of 534

Related

See all

Metadata

Authors
Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S. T., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., Huang, Y., Gonzales, P., Cabello, R., Orrell, C., Lama, J. R., Laher, F., Lazarus, E. M., Sanchez, J., Frank, I., Hinojosa, J., Sobieszczyk, M. E., Marshall, K. E., Mukwekwerere, P. G., Makhema, J., Baden, L. R., Mullins, J. I., Williamson, C., Hural, J., McElrath, M. J., Bentley, C., Takuva, S., Gomez Lorenzo, M. M., Burns, D. N., Espy, N., Randhawa, A. K., Kochar, N., Piwowar-Manning, E., Donnell, D. J., Sista, N., Andrew, P., Kublin, J. G., Gray, G., Ledgerwood, J. E., Mascola, J. R., & Cohen, M. S.
Affiliations
  • University of the Witwatersrand (ZA)
  • National Health Laboratory Service (ZA)
  • Emory University (US)
  • University of Zimbabwe (ZW)
  • From the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center (L.C., P.B.G., M.J., S.T.K., A.C.C., E.R., Y.H., K.E.M., J. Hural, M.J.M.E., C.B., S.T., N.E., A.K.R., N.K., D.J.D., J.G.K., G.G.), and the Departments of Global Health, Microbiology, and Medicine, University of Washington (J.I.M.), Seattle; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center (D.C.M.), and FHI 360 (N.S., P.A.), Durham, and the Institute for Global Health and Infectious Disease, University of North Carolina, Chapel Hill (M.S.C.) — both in North Carolina; the National Institute for Communicable Diseases of the National Health Laboratory Service (L.M.) and the Antibody Immunity Research Unit, Faculty of Health Sciences (L.M.), and the Perinatal HIV Research Unit, Faculty of Health Sciences (F.L., E.M.L., S.T.), University of the Witwatersrand, Johannesburg, the Desmond Tutu HIV Centre, Department of Medicine and Institute of Infectious Disease and Molecular Medicine ...
  • Brigham and Women's Hospital (US)
  • University of Cape Town (ZA)
  • Family Health International 360 (US)
  • South African Medical Research Council (ZA)
  • University of North Carolina at Chapel Hill (US)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2021-03-18
Volume
384
Issue
11
Pages
1003-1014
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa2031738
PMC
PMC8189692
OpenAlex
W3138945586
Cited by
538
References
31
Citations by year
2026: 87 · 2025: 108 · 2024: 98 · 2023: 98 · 2022: 78 · 2021: 66
FWCI
47.79
Type
journal article
Language
en
Open access
Licence
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • IRIS (submittedVersion)
  • UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
  • UNC Libraries
Funders
  • National Institute of Allergy and Infectious Diseases (P30 AI027757, UM1 AI068614, UM1 AI068618, UM1 AI068619, UM1 AI068635, UM1AI068613, UM1AI068617)
  • Intramural Research Program of the NIH, NIAID
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
HIV-1 prevention, broadly neutralizing antibodies, VRC01, HIV-1 acquisition, HIV-1 envelope glycoprotein, HIV-1 isolates
MeSH terms
Proof of Concept Study, Broadly Neutralizing Antibodies, Adolescent, Adult, Americas, Antibodies, Monoclonal, Double-Blind Method, Europe, Female, Humans, Male, HIV Antibodies, HIV-1, HIV Infections, Incidence, Africa South of the Sahara, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review